Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).

about

Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).

Item

http://www.wikidata.org/entity/Q55430075

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Dose-response of an extrafine ...... ose-ranging study (GlycoNEXT).

@en

Dose-response of an extrafine ...... ose-ranging study (GlycoNEXT).

@nl

type

Item

label

Dose-response of an extrafine ...... ose-ranging study (GlycoNEXT).

@en

Dose-response of an extrafine ...... ose-ranging study (GlycoNEXT).

@nl

prefLabel

Dose-response of an extrafine ...... ose-ranging study (GlycoNEXT).

@en

Dose-response of an extrafine ...... ose-ranging study (GlycoNEXT).

@nl

P1476

Dose-response of an extrafine ...... ose-ranging study (GlycoNEXT).

@en

P2093

Aida Emirova

http://www.w3.org/2001/XMLSchema#string

Debora Santoro

http://www.w3.org/2001/XMLSchema#string

Hélène Prunier

http://www.w3.org/2001/XMLSchema#string

Kai M Beeh

http://www.w3.org/2001/XMLSchema#string

Marie Anna Nandeuil

http://www.w3.org/2001/XMLSchema#string

P2860

Characterisation of COPD heterogeneity in the ECLIPSE cohort

A novel model-based approach for dose determination of glycopyrronium bromide in COPD

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.

Importance of inhaler devices in the management of airway disease.

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.

P304

1701-1711

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/COPD.S168493

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29872288

http://www.w3.org/2001/XMLSchema#string

P921

placebo

P932

5973313

http://www.w3.org/2001/XMLSchema#string